Topical delivery of vitamin d3: a randomized controlled pilot study

Mir Sadat-Ali, Dalal A Bubshait, Haifa A Al-Turki, Dakheel A Al-Dakheel, Wissam S Al-Olayani, Mir Sadat-Ali, Dalal A Bubshait, Haifa A Al-Turki, Dakheel A Al-Dakheel, Wissam S Al-Olayani

Abstract

Background and objective: The purpose of the present study is to explore the assessment if the transdermal delivery of vitamin D is feasible.

Methods: In 50 female Medical students, this study was conducted. Age, weight and height was taken, a detailed history and clinical examination was performed. Blood was drawn for 25 Hydroxy Vitamin D3 (25OHD) level. Two women had >30 ng/mL of 25OHD and was excluded from the study. The participants were divided into two groups of 24 in each arm. All participants equivocally agreed not to change their dietary habits and life style till the study was over. The study group of women were asked to apply; Top-D (Aloe Vera based- Vitamin D3) (Patency Pending) was developed at King Fahd Hospital of the University, AlKhobar with each gram of the Top-D cream delivering 5000 IU of vitamin D3. The second group used 1 gram of Aloe vera gel. The participants had no knowledge to which group they belong. A second blood sample was taken at the end of 3 months and the data was analyzed.

Results: The data of 48 women was available for analysis. The average age was 22.58 ± 1.95 years. The mean pre-treatment 25OHD in the study group was 12.05 ng/Ml ± 6.54 and post-treatment was 37.95 ng/mL ± 6.43 (P=0.001, CI<28.582 ). In control group pre-treatment 25OHD was 11.4 ng/mL ± 3.97 and post-treatment was 10.58ng/mL ± 3.03.

Conclusions: This randomized control study shows that vitamin D3 can safely be delivered through the dermal route. This route could be exploited in treating vitamin D deficiency.

Keywords: Medication Burden; Vitamin D; deficiency; route of administration.

Figures

Figure 1
Figure 1
25OHD in Control Group at pre and post placebo treatment.
Figure 2
Figure 2
25OHD levels pre and post treatment with Topical Vitamin D.

References

    1. Whistler D. Morbo puerili Anglorum, quem patrio idiomate indigenae vocant. Lugduni Batavorum: The Rickets. 1645:1–13.
    1. Glisson F. London: The Rickets diciteur; 1650. De Rachitide sive morbo puerili, qui vulgo; pp. 1–416.
    1. Hernigou P. Historical overview of rickets, osteomalacia, and vitamin D. Rev. Rhum. Engl. Ed. 1995 Apr;62(4):261–270.
    1. Mellanby E. Experimental rickets. Medical Research (G.B.) Special Report Series. 1921;SR-61:1–78.
    1. Sedrani SH, Elidrissy AW, El Arabi KM. Sunlight and vitamin D status in normal Saudi subjects. Am. J. Clin. Nutr. 1983 Jul;38(1):129–132.
    1. Sedrani SH. Low 25-hydroxyvitamin D and normal serum calcium concentrations in Saudi Arabia: Riyadh region. Ann. Nutr. Metab. 1984;28(3):181–185.
    1. Al-Turki SH, Sadat-Ali M, Al-Elq AH, Al-Mulhim FA, et al. 25-Hydoxyvitamin D levels among healthy Saudi Arabian women. Saudi Med. J. 2008 Dec;29(5):378–382.
    1. Sadat-Ali M, AlElq A, Al-Turki H, Al-Mulhim F, et al. Vitamin D levels in healthy men in eastern Saudi Arabia. Ann. Saudi Med. 2009 Sep-Oct;29(5):378–382.
    1. ElSammak MY, Al-Wossaibi AA, Al-Howeish A, Alsaeed J. Vitamin D deficiency in Saudi Arabs. Horm. Metab. Res. 2010;42:1–5.
    1. Al-Elq AM. The status of Vitamin D in medical students in the preclerkship years of a Saudi medical school. J. Family Community Med. 2012 Feb;19(2):100–104.
    1. Grant AM, Avenell A, Campbell MK, et al. RECORD Trial Group. Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): a randomized placebo-controlled trial. Lancet. 2005;365:1621–1628.
    1. Porthouse J, Cockayne S, King C, et al. Randomised controlled trial of calcium and supplementation with cholecalciferol (vitamin D3) for prevention of fractures in primary care. Br. Med. J. 2005;330:1003–1006.
    1. Jackson RD, LaCroix AZ, Gass M, et al. for the Women’s Health Initiative Investigators. Calcium plus vitamin D supplementation and the risk of fractures. N. Engl. J. Med. 2006;354:669–683.
    1. Avorn J. Medications and the Elderly. In: Rowe J, Besdine R, editors. Geriatric Medicine. 2d ed. Boston: Little, Brown; 1988.
    1. Kruse W, Koch-Gwinner P, Nikolaus T, Oster P, et al. Measurement of Drug Compliance by Continuous Electronic Monitoring: A Pilot Study in Elderly Patients Discharged from Hospital. Journal of the American Geriatrics Society. 1942;40:1151–1155.
    1. Nikolaus T, Kruse W, Bach M, Specht-Leible N, et al. Elderly Patients’ Problems with Medication. An In-Hospital and Follow-Up Study. European Journal of Clinical Pharmacology. 1996;49(4):255–259.
    1. Thomas BJ, Finnin BC. The transdermal revolution. Drug Discov. Today. 2004;9:697–703.
    1. Shi Y, Wei Z, Zhao H, Liu T, et al. Electrospinning of ibuprofen-loaded composite nanofibers for improving the performances of transdermal patches. J. Nanosci. Nanotechnol. 2013 Jun;13(6):3855–3863.
    1. Plaza-Villegas F, Heir G, Markman S, Khan J, et al. Topical pregabalin and diclofenac for the treatment of neuropathic orofacial pain in rats. Oral. Surg. Oral. Med. Oral. Pathol. Oral. Radiol. 2012 Oct;114(4):449–456.
    1. Derry S, Moore RA. Topical capsaicin (low concentration) for chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2012 Sep;12:9. doi: 10.1002/14651858.CD010111.
    1. Aggarwal N, Goindi S. Preparation and in vivo evaluation of solid lipid nanoparticles of griseofulvin for dermal use. J. Biomed. Nanotechnol. 2013 Apr;9(4):564–576.
    1. Ahad A, Al-Jenoobi FI, Al-Mohizea AM, Aqil M, et al. Transdermal delivery of calcium channel blockers for hypertension. Expert Opin. Drug. Deliv. 2013 Aug;10(8):1137–1153.
    1. Goodman MP. Are all estrogens created equal? A review of oral vs. transdermal therapy. J. Womens Health (Larchmt) 2012 Feb;21(2):161–169.
    1. Morrow DIJ, McCarron PA, Woolfson AD, Donnelly RF. Innovative Strategies for Enhancing Topical and Transdermal Drug Delivery. The Open Drug Delivery Journal. 2007:36–59.
    1. Williams AC. London: Pharmaceutical Press; 2003. Transdermal and topical drug delivery.
    1. Bronaugh RL, Maibach HI, editors. 2nd ed. New York: Marcel Dekker; 1989. Percutaneous Absorption.
    1. Segal E, Zinman C, Raz B, Ish-Shalom S. Low patient compliance--a major negative factor in achieving vitamin D adequacy in elderly hip fracture patients supplemented with 800IU of vitamin D3 daily. Arch. Gerontol Geriatr. 2009 Nov-Dec;49(3):364–367.
    1. Castelo-Branco C, Cortés VF, Ferrer M. Treatment persistence and compliance with a combination of calcium and vitamin D. Climacteric. 2010 Dec;13(6):578–584.
    1. Anfelix-Genovés J, Gil-Guillén VF, Orozco-Beltran D, Giner-Ruiz V, et al. Determinant factors of osteoporosis patients’ reported therapeutic adherence to calcium and/or vitamin D supplements: a cross-sectional, observational study of postmenopausal women. Drugs Aging. 2009;26(10):861–869.
    1. Díez A, Carbonell C, Calaf J, Caloto MT, et al. Observational study of treatment compliance in women initiating antiresorptive therapy with or without calcium and vitamin D supplements in Spain. Menopause. 2012 Jan;19(1):89–95.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe